Literature DB >> 531541

Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease.

O Selroos, T L Sellergren.   

Abstract

Thirty-nine sarcoidosis patients with pulmonary infiltrations (stage II) of less than 5 years duration and not treated earlier with corticosteroids were randomly allocated for treatment with methylprednisolone for 7 months or for observation without therapy. Every other treated patient was given the drugs daily and every other followed an alternate-day regimen. After 7 months the chest radiographic finding, the forced vital capacity and the diffusion capacity for carbon monoxide were superior in the treated group. There was no difference between the two drug regimens. After 24 and 48 months no statistically significant differences between the untreated and the treated groups were found.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 531541

Source DB:  PubMed          Journal:  Scand J Respir Dis        ISSN: 0036-5572


  11 in total

1.  Glucocorticosteroids and pulmonary sarcoidosis.

Authors:  O Selroos
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

2.  British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

Authors:  G J Gibson; R J Prescott; M F Muers; W G Middleton; D N Mitchell; C K Connolly; B D Harrison
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

3.  Suppression of the alveolitis in pulmonary sarcoidosis by oral corticosteroids.

Authors:  G A Rossi; G B Di Negro; E Balzano; E Cerri; O Sacco; B Balbi; A Venturini; R Ramoino; C Ravazzoni
Journal:  Lung       Date:  1985       Impact factor: 2.584

4.  Prognosis in sarcoidosis.

Authors:  J T Macfarlane
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-26

Review 5.  Corticosteroids for pulmonary sarcoidosis.

Authors:  N S Paramothayan; T J Lasserson; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 6.  Treatment of Sarcoidosis.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

7.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

8.  Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids.

Authors:  D S Goldstein; M H Williams
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

9.  Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study.

Authors:  Hee-Young Yoon; Hyeong Min Kim; Ye-Jee Kim; Jin Woo Song
Journal:  Respir Res       Date:  2018-08-28

10.  Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).

Authors:  Sheetu Singh; Bharat Bhushan Sharma; Mohan Bairwa; Dipti Gothi; Unnati Desai; Jyotsna M Joshi; Deepak Talwar; Abhijeet Singh; Raja Dhar; Ambika Sharma; Bineet Ahluwalia; Daya K Mangal; Nirmal K Jain; Khushboo Pilania; Vijay Hadda; Parvaiz A Koul; Shanti Kumar Luhadia; Rajesh Swarnkar; Shailender Nath Gaur; Aloke G Ghoshal; Amita Nene; Arpita Jindal; Bhavin Jankharia; Chetambath Ravindran; Dhruv Choudhary; Digambar Behera; D J Christopher; Gopi C Khilnani; Jai Kumar Samaria; Harpreet Singh; Krishna Bihari Gupta; Manju Pilania; Manohar L Gupta; Narayan Misra; Nishtha Singh; Prahlad R Gupta; Prashant N Chhajed; Raj Kumar; Rajesh Chawla; Rajendra K Jenaw; Rakesh Chawla; Randeep Guleria; Ritesh Agarwal; R Narsimhan; Sandeep Katiyar; Sanjeev Mehta; Sahajal Dhooria; Sushmita R Chowdhury; Surinder K Jindal; Subodh K Katiyar; Sudhir Chaudhri; Neeraj Gupta; Sunita Singh; Surya Kant; Zarir Udwadia; Virendra Singh; Ganesh Raghu
Journal:  Lung India       Date:  2020 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.